Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bright Green Co. stock logo
BGXX
Bright Green
$0.21
-4.5%
$0.24
$0.15
$1.16
$40.30M0.6689,319 shs221,982 shs
Safety Shot, Inc. stock logo
SHOT
Safety Shot
$1.20
-8.4%
$2.00
$0.31
$7.50
$59.06M1.9780,358 shs874,281 shs
United-Guardian, Inc. stock logo
UG
United-Guardian
$8.45
+5.6%
$7.93
$5.79
$9.74
$38.82M0.696,197 shs19,811 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$1.13
+4.6%
$1.29
$0.47
$1.82
$42.49M2.72454,206 shs280,362 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bright Green Co. stock logo
BGXX
Bright Green
0.00%-1.21%-11.71%+19.04%-81.25%
Safety Shot, Inc. stock logo
SHOT
Safety Shot
0.00%-13.04%-48.28%-68.50%+119,999,900.00%
United-Guardian, Inc. stock logo
UG
United-Guardian
0.00%+3.99%+12.52%-8.75%-11.43%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
0.00%+0.89%-9.60%+1.80%-24.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/AN/AN/AN/A
Safety Shot, Inc. stock logo
SHOT
Safety Shot
N/AN/AN/AN/AN/AN/AN/AN/A
United-Guardian, Inc. stock logo
UG
United-Guardian
1.21 of 5 stars
0.03.01.70.01.91.71.3
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2.9122 of 5 stars
3.53.00.00.03.22.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/A
Safety Shot, Inc. stock logo
SHOT
Safety Shot
N/AN/AN/AN/A
United-Guardian, Inc. stock logo
UG
United-Guardian
N/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.00
Buy$5.30369.03% Upside

Current Analyst Ratings

Latest UG, SHOT, UNCY, and BGXX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$3.00
4/4/2024
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$9.00
4/1/2024
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.50
3/14/2024
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.50
3/5/2024
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.50
2/14/2024
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Noble Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$6.00
(Data available from 5/12/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/A$0.06 per shareN/A
Safety Shot, Inc. stock logo
SHOT
Safety Shot
$200K295.32N/AN/A$0.22 per share5.45
United-Guardian, Inc. stock logo
UG
United-Guardian
$10.89M3.56$0.58 per share14.45$2.48 per share3.41
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$680K62.50N/AN/A($0.11) per share-10.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bright Green Co. stock logo
BGXX
Bright Green
-$13.13M-$0.08N/AN/AN/A-101.64%-57.83%5/27/2024 (Estimated)
Safety Shot, Inc. stock logo
SHOT
Safety Shot
-$15.08M-$0.71N/AN/A-367.77%-226.38%-132.81%5/20/2024 (Estimated)
United-Guardian, Inc. stock logo
UG
United-Guardian
$2.58M$0.6014.08N/A23.71%24.26%21.11%8/9/2024 (Estimated)
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$30.54M-$1.55N/AN/AN/AN/AN/A-96.37%5/21/2024 (Estimated)

Latest UG, SHOT, UNCY, and BGXX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Bright Green Co. stock logo
BGXX
Bright Green
N/A-$0.03-$0.03-$0.03N/AN/A
3/28/2024Q4 2023
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.18-$0.16+$0.02-$0.16N/AN/A
3/22/2024Q4 2023
United-Guardian, Inc. stock logo
UG
United-Guardian
N/A$0.16+$0.16$0.16N/A$2.61 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/A
Safety Shot, Inc. stock logo
SHOT
Safety Shot
N/AN/AN/AN/AN/A
United-Guardian, Inc. stock logo
UG
United-Guardian
$0.505.92%-49.58%83.33%N/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bright Green Co. stock logo
BGXX
Bright Green
0.02
0.04
0.04
Safety Shot, Inc. stock logo
SHOT
Safety Shot
N/A
2.14
1.92
United-Guardian, Inc. stock logo
UG
United-Guardian
N/A
7.99
7.19
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
0.76
0.76

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bright Green Co. stock logo
BGXX
Bright Green
7.83%
Safety Shot, Inc. stock logo
SHOT
Safety Shot
12.55%
United-Guardian, Inc. stock logo
UG
United-Guardian
23.16%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%

Insider Ownership

CompanyInsider Ownership
Bright Green Co. stock logo
BGXX
Bright Green
51.38%
Safety Shot, Inc. stock logo
SHOT
Safety Shot
23.09%
United-Guardian, Inc. stock logo
UG
United-Guardian
29.00%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
42.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bright Green Co. stock logo
BGXX
Bright Green
5190.17 million92.46 millionOptionable
Safety Shot, Inc. stock logo
SHOT
Safety Shot
849.22 million37.86 millionOptionable
United-Guardian, Inc. stock logo
UG
United-Guardian
234.59 million3.26 millionNot Optionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
1237.61 million21.81 millionNot Optionable

UG, SHOT, UNCY, and BGXX Headlines

SourceHeadline
3 Top Penny Stocks to Buy for Explosive Returns: April Edition3 Top Penny Stocks to Buy for Explosive Returns: April Edition
finance.yahoo.com - May 9 at 3:40 AM
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper SandlerThese 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
finance.yahoo.com - April 29 at 2:34 PM
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial PositioningBuy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
markets.businessinsider.com - April 12 at 1:16 PM
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceUnicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
globenewswire.com - April 10 at 7:03 AM
Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKDUnicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD
markets.businessinsider.com - April 4 at 4:58 PM
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial FootingBuy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
markets.businessinsider.com - April 2 at 4:34 AM
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023
investorplace.com - March 28 at 11:31 PM
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
finance.yahoo.com - March 28 at 8:12 PM
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
globenewswire.com - March 28 at 4:15 PM
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association CongressUnicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
globenewswire.com - March 25 at 7:03 AM
Unicycive reports progress in kidney injury treatment trialUnicycive reports progress in kidney injury treatment trial
investing.com - March 16 at 12:26 AM
Buy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate ProspectsBuy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospects
markets.businessinsider.com - March 14 at 3:38 PM
Unicycive Announces $50 Million Private PlacementUnicycive Announces $50 Million Private Placement
globenewswire.com - March 14 at 7:03 AM
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT ConferenceUnicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
globenewswire.com - March 13 at 7:03 AM
Unicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)Unicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
finanznachrichten.de - March 9 at 1:24 AM
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
globenewswire.com - March 7 at 4:12 PM
Buy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug DesignationBuy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug Designation
markets.businessinsider.com - March 6 at 4:12 PM
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant PatientsUnicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
globenewswire.com - March 4 at 7:03 AM
Unicycive Therapeutics Stock (NASDAQ:UNCY), Short Interest ReportUnicycive Therapeutics Stock (NASDAQ:UNCY), Short Interest Report
benzinga.com - February 25 at 9:25 AM
Unicycive Therapeutics Stock (NASDAQ:UNCY), Analyst Ratings, Price Targets, PredictionsUnicycive Therapeutics Stock (NASDAQ:UNCY), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 25 at 9:25 AM
Unicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46Unicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46
msn.com - February 24 at 11:54 PM
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
finance.yahoo.com - February 14 at 9:33 AM
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
globenewswire.com - February 14 at 7:03 AM
Were Keeping An Eye On Unicycive Therapeutics (NASDAQ:UNCY) Cash Burn RateWe're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
finance.yahoo.com - February 6 at 8:24 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bright Green logo

Bright Green

NASDAQ:BGXX
Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.
Safety Shot logo

Safety Shot

NASDAQ:SHOT
Safety Shot, Inc., a wellness and functional beverage company, researches and develops over-the-counter products and intellectual property. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It also develops Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women's sexual wellness; and NoStingz, a jellyfish sting prevention sunscreen. The company sells its products through distributors, retailers, and e-commerce websites. The company was formerly known as Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. in September 2023. Safety Shot, Inc. was incorporated in 2018 and is based in Jupiter, Florida.
United-Guardian logo

United-Guardian

NASDAQ:UG
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.
Unicycive Therapeutics logo

Unicycive Therapeutics

NASDAQ:UNCY
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.